/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the...

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

PRISM-EXT shows data consistent with those of PRISM3, which provided significant improvement compared with the placebo through 8 weeks and 24 weeks post-treatment.

Within the local setting of our study, CDI within 12 months post-LT is of low severity, associated with pre-LT antibiotic exposure and longer hospital stay but no survival impact after LT. Rifaximin use pre-LT reduced the risk of CDI post-LT. This article is protected by copyright. All rights reserv …

Clostridioides difficile infection (CDI) is the major identifiable cause of antibiotic-associated diarrhea. The emergence of hypervirulent C. difficile strains has led to increases in both hospital- and community-acquired CDI. Furthermore, CDI relapse from hypervirulent strains can rea …

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Many antibiotics prescribed in the United States are unnecessary or inappropriate. Improved antibiotic stewardship is needed, not only to curb the threat of antibiotic resistance but also to avoid exposing patients to unnecessary risks.

C. difficile is one of the leading causes of hospital-acquired infections. Arrieta-Ortiz et al. report three predictive models (with extensive validations) for dissecting interplay of regulation and metabolism that underlies host-pathogen interactions of C. difficile. The C. difficile interactive web portal provides access to these models, compiled datasets, and algorithms.

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent C. difficile infection (CDI).

BASEL, Switzerland & CAMBRIDGE, Mass. & HORSHOLM, Denmark, November 10, 2021--Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics, a leading microbiome therapeutics company, announced today a collaboration to manufacture SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI). Under the terms of the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbio

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C. difficile Infection (CDI) were presented at the 9th International C. diff Conference & Health Expo entitled: "Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect?" The presentation was made on Novembe

Ferring Pharmaceuticals today announced positive results across all five of its prospective trials for a live biotherapeutic designed to reduce recurrent C. difficile infection (rCDI).

Researchers evaluated the safety and efficacy of the investigational, microbiota-based, live biotherapeutic RBX2660 for treatment of recurrent C difficile infection.

A University of California, Irvine-led study suggests that the glucosyltransferase domain (GTD) is an ideal molecular target for therapeutic interventions for Clostridioides difficile infection (CDI). ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C. difficile Infection (CDI) will be presented at the 9th Annual International C. diff Conference & Health Expo. taking place virtually on November 4-5, 2021.

LAS VEGAS — CP101, an investigational microbiome therapeutic, restored microbiome diversity and prompted a sustained clinical cure among patients with recurrent Clostridioides difficile infection, according to a presentation. “Recurrent C. difficile infection is common following standard of care antibiotics and remains a significant burden on the health care system. Treatment

EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that...

Freeze-dried human stool may offer advantages for the treatment of C difficile infections.

New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeks Additional PRISM3 microbiome data show CP101 engraftment leads to an increase in intestinal microbiome

Clostridioides difficile is an antibiotic-resistant bacterium that causes serious, toxin-mediated enteric disease in humans and animals. Gut dysbiosis and resultant alterations in the intestinal bile acid profile play an important role in the pathogenesis of C. difficile infection (CDI). Restoration of the gut microbiota and re-establishment of bacterial bile acid metabolism using fecal microbiota transplantation (FMT) has been established as a promising strategy against this disease, although this method has several limitations. Thus, a more defined and precise microbiota-based approach using bacteria that biotransform primary bile acids into secondary bile acids could effectively overcome these limitations and control CDI. Therefore, a screening pipeline was developed to isolate bile acid converting bacteria from fecal samples. Dogs were selected as a model CDI-resistant microbiota donor for this pipeline, which yielded a novel Peptacetobacter hiranonis strain that possesses unique anti- C. difficile properties, and both bile acid deconjugation and 7-α dehydroxylating activities to perform bile acid conversion. The screening pipeline included a set of in vitro tests along with a precision in vivo gut colonization and bile acid conversion test using altered Schadler flora (ASF) colonized mice. In addition, this pipeline also provided essential information on the growth requirements for screening and cultivating the candidate bacterium, its survival in a CDI predisposing environment, and potential pathogenicity. The model pipeline documented here yielded multiple bile acid converting bacteria, including a P. hiranonis isolate with unique anti- C. difficile biotherapeutic potential, which can be further tested in subsequent preclinical and human clinical trials. ### Competing Interest Statement The authors have declared no competing interest.